Valeant CEO sees new drug pricing environment ahead
NEW YORK Oct 19 (Reuters) - Valeant Pharmaceuticals International Inc CEO J. Michael Pearson said on Monday that outside pressures are creating a new pricing environment for all pharmaceutical companies and that Valeant expects to keep increases to 10 percent or less next year.
During a conference call with investors in which he defended the company's drug pricing strategy, Pearson said that Valeant has begun during the past two years to increase sales volumes as a percentage of growth compared with price increases.
(Reporting by Caroline Humer)
© Thomson Reuters 2017 All rights reserved.